Bone loss is recognized as worsening the quality of life in long-term survivors of Allo-SCT. This study evaluated the risk factors associated with bone loss and the role of zoledronic acid in preventing bone loss in allogeneic recipients. Fifty-three patients who underwent HLAmatched Allo-SCT were evaluated for their bone mineral density (BMD) in the lumbar spine and femoral neck at regular intervals. Zoledronic acid (4 mg) was given i.v. to 18 patients (ZA patients) at 2 months after SCT and then every 3 months until 2 years. Grade 2-4 acute GVHD was associated with bone loss (odds ratio (OR) ¼ 4.90, 95% confidence interval (CI) ¼ 1.41-16.99; P ¼ 0.012) at 1 year after SCT, whereas extensive chronic GVHD and steroid use were both unfavorable prognostic factors (OR ¼ 9.00 and 7.22, 95% CI ¼ 1.52-53.40 and 1.44-36.22; P ¼ 0.016, respectively) in terms of osteopenia/ osteoporosis at 2 years after transplantation. The use of zoledronic acid significantly prevented bone loss in the femoral neck as well as the spine (OR ¼ 0.18, 95% CI ¼ 0.05-0.69, P ¼ 0.012). Therefore, BMD measurements and the use of zoledronic acid are recommended in cases of GVHD or long-term steroid use after Allo-SCT to prevent bone loss and threatening skeletal events.
Introduction
With the improved outcomes of Allo-SCT for hematologic malignancies, long-term complications have assumed greater importance. For example, osteoporotic fracture or avascular necrosis of the femoral head is not uncommon in allogeneic recipients, [1] [2] [3] [4] whereas the risk factors predicting bone loss after SCT include chemotherapeutic agents, immunosuppressants, immobilization and hypogonadism. 3, 5 Earlier studies have shown that the pattern of bone loss after Allo-SCT is somewhat different from other forms of osteoporosis, being more persistent and severe in cortical bones, such as the femur neck, than in trabecular bones, such as the spine. 1, 6, 7 Although anti-reabsorptive treatment with bisphosphonate is effective in postmenopausal or senile osteoporosis, few data are available on the preventive use of bisphosphonate in allogeneic recipients. In an earlier study, pamidronate was shown to play a positive role in preventing bone loss after Allo-SCT in the spine but not in the femoral neck. 8 Zoledronic acid, a third-generation nitrogen-containing bisphosphonate, has a high potency and is thus expected to help prevent bone loss in allogeneic recipients when used after transplantation. This study therefore evaluated the prognostic factors for bone loss and effect of zoledronic acid on the lumbar and femoral bone mineral density (BMD) in patients who underwent HLA-matched Allo-SCT for hematologic malignancies.
Patients and methods
Patients and transplantation procedure Twenty-eight patients who underwent HLA-matched Allo-SCT and agreed on the use of zoledronic acid were enrolled from October 2002 to December 2006. Among them, 18 patients who survived over 1 year following the SCT were selected for analysis. Patients with any disorders related to bone and mineral metabolism, such as renal failure, hyperparathyroidism or thyroid disorders, were excluded. The institutional review board of Kyungpook National University Hospital (KNUH) approved this exploratory clinical trial. For the control group, 38 patients who underwent HLA-matched Allo-SCT at KNUH from February 2000 to December 2006 and survived over 1 year following the SCT were selected for comparison.
The enrolled patients received conditioning regimens according to KNUH protocol, as described earlier, 9 where BU/CY (BuCy2) or BU/fludarabine (BF) were mostly used. The acute GVHD (aGVHD) prophylaxis consisted of MTX and CYA or FK506. CYA was started at a dose of 5 mg/kg/day (continuous i.v.) on day À1, reduced to a dose of 2.5 mg/kg/day i.v. on day þ 7 and then changed to a dose of 3 mg/kg/day (twice daily p.o.) when tolerable. FK506 was used in an unrelated SCT setting with a starting dose of 0.05 mg/kg. MTX was administered at 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6 and 11. The last dose of MTX was omitted in the case of mucositis over grade 4 or renal impairment. The allogeneic donor hematopoietic stem cells were infused on day 0 using a standard infusion technique. Infection prophylaxis consisted of ciprofloxacin (250 mg twice daily p.o.)/metronidazole (500 mg thrice daily p.o.)/fluconazole (100 mg once daily p.o.), beginning with the initiation of conditioning, and acyclovir (600 mg twice daily p.o.) from day À1. Co-trimoxazole was started after engraftment. Ursodeoxycholinic acid was used as venoocclusive disease prophylaxis beginning with the initiation of conditioning.
Preventive medication for osteopenia/osteoporosis Zoledronic acid (Zometa, 4 mg, Norvatis Pharmaceuticals Corp., Basel, Switzerland) was administrated at 2 months after transplantation, and then every 3 months until 2 years. All the patients were given calcium carbonate (1 g/day) orally from discharge to 2 years, but vitamin D and sex hormone replacement were not administered routinely.
Bone density and fracture assessment Bone mineral density measurements were performed for the lumbar spine and femur neck before the SCT and at 6, 12 and 24 months after the SCT using dual-energy X-ray absorptiometry (DXA) (Lunar Prodigy, GE Lunar Corp., Madison, WI, USA). The individual BMD values were expressed as g/cm 2 , T-or Z-scores, and the precision was 1.0% at both locations. Bone events were assessed with radiologic images, if indicated, and MRI was used for confirmation.
Gonadal status assessment
Serum FSH (follicular stimulating hormone), LH (luteinizing hormone) and 17b-estradiol, plus testosterone levels were determined before transplantation, at 6 and 12 months, and then annually on the same schedule as the BMD. All the measurements were performed using commercially available kits and analyzed with MODU-LAR ANALYTICS E170 (Roche Diagnostics, Mannheim, Germany) using an electrochemiluminescence immunoassay (ECLIA).
Definition
Engraftment was confirmed by the peripheral blood counts (myeloid: peripheral ANC of more than 0.5 Â 10 9 /l, megakaryocyte: peripheral plt count of more than 20 Â 10 9 /l for 3 consecutive days without requiring transfusion). The diagnosis of aGVHD was performed as described earlier, on the basis of consensus criteria. [10] [11] [12] The diagnosis of chronic GVHD (cGVHD) was made on the basis of the revised Seattle criteria. 13 The day of onset of overall and extensive cGVHD was defined as the date of the initiation of clinical sign(s) of cGVHD or the date of histological confirmation. High-risk disease status was defined as acute leukemia beyond the first remission, CML beyond the first chronic phase, and multiple relapsing or chemoresistant malignancies.
Statistical analysis
A statistical analysis using Student's t-test was performed for paired and unpaired data, as appropriate, to compare the patients treated with and without zoledronic acid. To evaluate the risk factors for bone loss, we divided the enrolled patients into two groups according to the median values of the difference in Z-score of BMD at 1 and 2 years after SCT, and then the associations between the groups and variables possibly associated with reduced BMD (age, sex, risk status of hematologic disease, stem cell source, type of conditioning, dose of infused cells, use of steroid, existence of acute or chronic GVHD, gonadal dysfunction and use of zoledronic acid) were analyzed using a logistic regression analysis. The basic statistical data were obtained using an SPSS software package (SPSS 11.5 Inc. Chicago, IL, USA). Statistical significance is represented by twotailed P-values. A cutoff value of 0.05 was adopted for all the statistical analyses.
Results

Clinical features of patients
The characteristics of the 53 patients are summarized in Table 1 . The median age was 34 (range, 15-68) years and most (66.0%) had acute leukemia. Transplants were performed as a peripheral blood SCT in 42 (72.9%) 
Transplantation outcomes
The median day of engraftment was 13 (range, 10-21) days for the neutrophils and 12 (range, 9-161) days for the plts (Table 2) . Grade 2-4 aGVHD was observed in 20 (37.7%) patients, and extensive cGVHD in 15 (28.3%) patients. During the median follow-up of 1071 (range, 384-3227) days, four patients (7.4%) experienced relapses and three died from primary diseases or infections associated with cGVHD.
Baseline evaluation of bone turnover and BMD after SCT The mean baseline BMD (Z-score) was within normal limits for all the measurement sites, where only two patients with myelodysplastic syndrome and severe aplastic anemia showed osteoporosis according to the WHO definition ( Table 2 ). 14 Bone loss was rapid during the first year in both the spine and femur neck, and continuous bone loss was observed in the spine (Figure 1 ). During the follow-up period, five (9.4%) bone events were reported, including three avascular necrosis and two fractures of the femur neck ( Table 2 ). The cumulative incidence of bone events and fractures was 16.1 and 4.4%, respectively (Figure 2 ).
Factors associated with bone loss after SCT Univariate analyses of potential risk factors were performed (Table 3) . Myleoablative conditioning, a higher dose of infused stem cells and the existence of grade 2-4 aGVHD were all associated with bone loss at 1 year after SCT, whereas extensive cGVHD and the use of steroids for more than 3 months were risk factors for bone loss at 2 years after SCT. However, preventive use of zoledronic acid was inversely related to bone loss at both 1 and 2 years. 
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In the multivariate analysis, extensive cGVHD and the use of steroids were both risk factors for bone loss at 2 years (odds ratio (OR) ¼ 58.39; 95% confidence interval (CI) ¼ 1.42-2396.40; P ¼ 0.032 and OR ¼ 21.30; 95% CI ¼ 1.44-36.22; P ¼ 0.032), whereas zoledronic acid had a protective role in bone loss at 1 year (OR ¼ 0.142; 95% CI ¼ 0.03-0.63; P ¼ 0.010) ( Table 4) .
Comparison of BMD according to use of zoledronic acid and FSH level
There were no definite differences in patient characteristics and transplantation procedures except for a higher dose of infused CD3 cells in the zoledronic acid group (Table 5 ). Figure 3 shows the baseline changes in the BMD according to the preventive use of zoledronic acid in the spine and the femur neck. For the spine, the control patients showed significant changes over time, whereas the zoledronic acid patients showed a stable BMD after SCT. For the femur neck, the control showed a significant bone loss at 6 months, whereas the patients given zoledronic acid showed early BMD recovery. The changes in BMD level at 1 year were no different between the normal and elevated FSH patients.
Discussion
This study shows that the use of zoledronic acid may play a preventive role in transplantation-related bone loss. Indeed, earlier studies have reported that age, hypogonadism, the presence of GVHD and subsequent use of steroids, immobility, and chemotherapeutic agents or immunosuppressants are closely related to bone loss. 3, 5, 15 Although anti-reabsorptive treatments have been shown to improve bone loss and decrease the rate of fractures in postmenopausal osteoporosis, [16] [17] [18] evaluating their role in a transplant setting is quite difficult, as multifactorial factors are related to bone loss. As supplements of calcium, vitamin D and sex hormone replacement have failed to prevent bone loss after SCT in earlier studies, 19 more potent anti-reabsorptive treatments, such as bisphosphonate, have been evaluated, where pamidronate, the second generation of bisphosphonate, has been found to prevent bone loss in the spine after SCT but not in the femur neck. 8 Meanwhile, zoledronic acid is a potent nitrogen-containing bisphosphonate, which is also more convenient than pamidronate because of its short infusion time. Thus, it was suggested that zoledronic acid may play a role in preventing bone loss after SCT in the femur neck, as well as in the spine, and that it can be used more comfortably in the SCT setting. From the results in this study, although the bone loss in the spine was more prominent than it was in the femoral neck after transplantation, which differed from other study results, 3, 6, 7 the use of zoledronic acid was found to have a preventive effect on bone loss in the femoral neck as well as in the spine. Although several studies have already shown the protective effect of zoledronic acid on bone loss after Allo-SCT, 6,20,21 the schedules were quite different from that used in this study, where zoledronic acid was administered earlier and over a longer time period after transplantation.
In this study, zoledronic acid was started 2 months after transplantation and then used every 3 months on the basis of a 4 mg i.v. infusion, yet significant bone loss was observed at 6 months and prolonged bone loss until 3 years after SCT. Although the baseline BMD scores for the enrolled patients were mostly within normal limits, several studies have shown the presence of osteopenia or osteoporosis in 20-30% of patients before they underwent SCT, 19 indicating that intensive chemotherapy is one cause of osteopenia/osteoporosis. Furthermore, significant bone loss after chemotherapy and the preventive role of zoledronic acid have also been observed in a breast cancer setting. 22, 23 These results indicate that early BMD control is most important in patients at risk. As the BMD for the lumbar spine at 2 years was stable in the zoledronic acid patients, although still lower than the baseline in the control patients, the long-term use of zoledronic acid may offer benefits in terms of maintaining bone density, especially in patients with cGVHD.
In solid tumors that have metastasized to the skeleton, such as breast or prostatic cancer, and hematologic malignancies, such as myeloma, bisphosphonate has shown Table 5 Comparison according to use of zoledronic acid antitumor effects in vivo, as well as in vitro, by indirectly inhibiting tumor invasion through the inhibition of bone resorption, 24 angiogenesis 25 and immune modulation, 26, 27 along with direct antitumor activity through apoptosis, proliferation and cell adhesion. 28, 29 Thus, similar to myeloma, as leukemia and myelodysplastic syndrome wholly originate in the BM, it is possible that potent bisphosphonates may have an anti-leukemic effect, as suggested from earlier in vitro studies. [30] [31] [32] In this study, no relapses were observed among the zoledronic acid patients, whereas four relapses were experienced among the control patients. Nonetheless, a definite association between zoledronic acid and relapses was difficult to establish due to the clinical differences between the two groups of patients. A further study is therefore warranted to evaluate the antitumor effect of bisphosphonate in hematological patients receiving chemotherapy or SCT.
In summary, GVHD and steroid use were identified as major risk factors for Allo-SCT-associated bone loss, whereas the use of zoledronic acid in allogeneic recipients was found to prevent bone loss in the femoral neck as well as in the spine. Thus, for patients with chronic GVHD, long-term use of zoledronic acid should be considered to prevent bone loss and for threatening skeletal events. However, the optimal time and duration of zoledronic acid administration still requires clarification in future studies.
